SCHEDULE 13G/A: BlackRock Discloses 6.4% Passive Stake in Voyager Therapeutics
Beneficial Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.4% beneficial ownership stake in Voyager Therapeutics, Inc. as of March 31, 2025.
Summary
- BlackRock, Inc. has filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership in Voyager Therapeutics, Inc.
- As of March 31, 2025, BlackRock, Inc. beneficially owns 3,525,532 shares of Voyager Therapeutics, Inc. Common Stock.
- This represents 6.4% of the total outstanding Common Stock of Voyager Therapeutics, Inc.
- BlackRock holds sole voting power over 3,467,343 shares and sole dispositive power over 3,525,532 shares.
- No shared voting or dispositive power is reported.
- The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- Several BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Fund Advisors, are identified as entities that beneficially own 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, carrying a neutral sentiment. It does not contain positive or negative operational or financial news about the issuer, only a statement of an institutional investor's stake.
Future Outlook
NA
Industry Context
This Schedule 13G filing indicates a passive ownership stake by a major institutional investor, BlackRock, in Voyager Therapeutics, Inc. Such filings are routine disclosures by large asset managers when their holdings in a company cross certain thresholds (typically 5% or more) and are held for investment purposes without intent to influence control. It reflects BlackRock's continued or adjusted position in the biotechnology sector, specifically in a company focused on gene therapy.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, which can offer some stability or validation of the company's investment profile.
- Management: Awareness of a large, passive institutional investor on their shareholder register.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of execution of the Power of Attorney by BlackRock, Inc. |
| 03/31/2025 | Date of event which requires filing of this statement (reporting period end date). |
| 04/24/2025 | Signature date of the Schedule 13G filing by BlackRock, Inc. |
Keywords
BlackRock, Voyager Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.